1/67
Looks like no tags are added yet.
GLP-1
⢠Secreted from L-cells in the distal intestinal mucosa
⢠Rises within minutes of food ingestion
⢠Stimulates insulin secretion
⢠Suppresses glucagon secretion
⢠Slows gastric emptying
⢠Increases satiety (promotes fullness and decreases food intake)
GIP
⢠Secreted by K-cells in the intestine
⢠Increases insulin secretion
⢠No effect on glucagon, gastric motility, or satiety
Dipeptidyl Peptidase-4 (DPP-4)
GLP-1 and GIP are rapidly inactivated by ___________________________
Sodium glucose cotransporter-2 (SGLT-2)
Responsible for ~90% of filtered glucose reabsorption
180 mg/dL
Normal renal threshold for glucosuria occurs at plasma glucose of ___________________
ā¢Medical nutrition therapy [MNT], physical activity, weight loss, smoking cessation, and psychological support
-Initial weight loss goal of 5%
-Carbohydrate counting
Lifestyle Modifications for T2DM
Lifestyle Modifications + Metformin
What is the first step to Overall Approach of the Management of T2DM
Metformin
the preferred initial pharmacologic agent for the treatment of Type 2 Diabetes
Metformin
⢠Decreases hepatic glucose production*
⢠Activation of AMP-activated protein kinase in hepatocytes
⢠Decreases intestinal glucose absorption, increased insulin sensitivity
Metformin
Indications:
T2DM treatment, polycystic ovarian syndrome (PCOS)
Off-label uses:
T2DM prevention, gestational DM, antipsychotic-induced weight gain
Biguanide
What type of drug is metformin?
Metformin
BBW: Drug accumulation can lead to lactic acidosis Risk is increased in moderate-to-severe renal disease or hypoperfusion (hepatic impairment, CHF, sepsis, dehydration, excessive alcohol consumption)
Metformin
ADVERSE EFFECTS:
-Diarrhea (transient and dose dependent)
⢠B12 deficiency --> macrocytic anemia
⢠Metallic taste
⢠Rare: Lactic acidosis, hepatitis
Metformin
-Contraindicated with Radiocontrast dye
-Discontinue on the day of procedure and resume 2-3 days later due to risk of acute kidney injury from dye
-A1C
-hepatic function
-renal function
-B12
What should you monitor for in a patient taking metformin?
Patient With ASCVD, CKD, & HF
When do you use a Combination Therapy for T2DM
GLP-1 Receptor Agonist or SGLT2-Inhibitor
If patient has established ASCVD or is at high risk of developing ASCVD, has established CKD, or established HF, add on a ________________________ or ______________________________
SGLT2-Inhibitor
If a pt with T2DM has HF or CKD that predominates, what treatment addition is preferred?
GLP-1 Receptor Agonists
-Synthetic GLP-1; stimulate "incretin effect" and promote insulin secretion from pancreas in response to high oral glucose levels (resistant to DPP-4 degradation)
⢠Suppress inappropriate glucagon secretion; slow gastric emptying, which increases satiety
-Exenatide
-Liraglutide
-Dulaglutide
-Lixisenatide
-Semaglutide
GLP-1 Receptor Agonists
GLP-1 Receptor Agonists
Indications:
-T2DM
-weight management
⢠Reduction of major adverse CV events (MACE) in adults with T2DM with established CV disease
-Liraglutide
-Semaglutide
-Dulaglutide
GLP-1 RAs that have proven CV benefit
Liraglutide
GLP-1 RA that can reduce CKD progression
GLP-1 Receptor Agonists
Contraindications
⢠Hypersensitivity, history of or family history of medullary thyroid carcinoma (MTC) or in patients with multiple
endocrine neoplasia syndrome type 2
(MEN2)
GLP-1 Receptor Agonists
ADVERSE EFFECTS:
⢠GI Intolerance (Nausea, bloating, constipation)
⢠Acute renal failure has been reported
⢠Weight loss
⢠Injection site reactions, acute pancreatitis (rare)
Tirzepatide
-Agonists for GLP-1 and GIP
-Once a week subcutaneous injection
-A Novel, Dual-Targeted Treatment for Type 2 Diabetes
Tirzepatide
ADVERSE EFFECTS:
-stomach pain
-n/v
-pancreatic and gall bladder issues
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)
-Inhibition of SGLT-2 in the proximal renal tubules, to block glucose reabsorption
⢠Enhance renal excretion of glucose
-Canaglifozin
-Dapaglifozin
-Empaglifozin
-Ertugliflozin
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)
Indications:
⢠T2DM (ASCVD risk reduction, HF hospitalizations, CKD progression)
⢠HF
Canaglifozin
-SGLT2-i
-for T2DM, reduced MACE in adulst with T2DM and CVD
-reduced ESRD, doubling of SCr, CV death, and HHF in adults with T2DM and diabetic nephropathy with albuminuria
Dapagliflozin
-SGLT2-i
-for T2DM, and reduces risk of HHF in adults with T2DM and establish CVD or multiple CV risk factors
-reduced risk of CV death and HHF in adults with HFrEF
-new indication for pts with CKD with and without T2DM to reduce risk of kidney failure and CV or renal death
Empaglifozin
-SGLT2-i
-for T2DM and reduced risk fo CV death in adults with T2DM and established CVD
Ertuglifozin
-SGLT2-i
-only FDA labeled indication is for T2DM
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)
Contraindications
⢠Hemodialysis
⢠eGFR
45
SGLT2-i has a Less efficacy eGFR < _______ mL/min
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2-i)
ADVERSE EFFECTS:
⢠Genital mycotic infections (vaginal yeast infections in females), UTIs
⢠Osmotic diuresis, hypotension, hypovolemia
⢠Weight loss
⢠Amputations (boxed warning)
⢠Bone fractures
⢠Euglycemic ketoacidosis risk
⢠ā TG with slight ā HDL and LDL
-A1C
-Renal Function
-Electrolytes
-BP
-Lipid Panel
what should you monitor in a pt that is taking a SGLT2-i
⢠Dipeptidyl peptidase 4 inhibitor (DPP-4i)
⢠GLP-1 RA
⢠SGLT2-i
⢠Thiazolidinedione (TZD)
Combination Therapy for T2DM that need to minimize hypoglycemia
⢠GLP-1 RA with good efficacy for weight loss
⢠SGLT2-I
Combination Therapy for T2DM that need to minimize weight gain or promote weight loss
⢠Sulfonylurea (SU)
⢠TZD
Combination Therapy for T2DM that need to prohibit high costs
Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)
ADVERSE EFFECTS:
⢠Most common: Nasopharyngitis, upper respiratory tract infections
⢠Heart failure (avoid saxagliptin and alogliptin)
⢠Severe pancreatitis (rare)
⢠Joint pain (FDA-warning)
⢠Hypersensitivity: urticaria, angioedema, anaphylaxis, Stevens-Johnson syndrome
Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)
-Inhibit dipeptidyl peptidase-4, the enzyme responsible for the breakdown of GLP-1 and GIP (incretin hormones), to allow for increase in circulating incretins, including GLP-1
⢠Decrease glucagon production
⢠Improve insulin response to high glucose levels
⢠Do not significantly alter gastric emptying, with limited effects on satiety and weight loss
-Sitagliptin
-Saxagliptin
-Linagliptin
-Alogliptin
Dipeptidyl Peptidase-4 Inhibitors (DPP-4i)
Thiazolidinediones (TZD)
-Binds to the peroxisome proliferator activator receptor-gamma (PPAR- gamma), located on fat and vascular cells, which leads to transcription of several genes involved in glucose and lipid metabolism
⢠Enhances insulin sensitivity at muscle, fat, and liver to directly reduce insulin resistance
-Pioglitazone
-Rosiglitazone
Thiazolidinediones (TZD)
Thiazolidinediones (TZD)
A second-line therapy to add on to metformin; consider where need to minimize hypoglycemia OR minimize costs
⢠Can be used as monotherapy for patients who cannot take metformin
Thiazolidinediones (TZD)
Contraindications
⢠NYHA Class III/IV heart failure (HF)
Thiazolidinediones (TZD)
ADVERSE EFFECTS:
⢠Fluid retention and edema
⢠Macular edema
⢠Weight gain (5 kg)
⢠BBW: HF - may exacerbate or cause HF
⢠Bladder cancer?
⢠Fractures
Sulfonylureas (SU)
-Bind to sulfonylurea receptor (SUR1) to close ATP-sensitive K+ channels in the β-cell membrane leading to an influx of calcium ions and exocytosis of insulin containing granules eventually ā pancreatic secretion of insulin
-Glipizide
-Glimepiride
-Glyburide
Sulfonylureas (SU)
Sulfonylureas (SU)
A second-line therapy to add on to metformin; consider where need for cost minimization
⢠Can be used as monotherapy for patients who cannot take metformin
Sulfonylureas (SU)
ADVERSE EFFECTS:
⢠Hypoglycemia: most common adverse effect
⢠Weight gain
⢠Less common: skin rash, hemolytic anemia, GI upset
⢠T1DM or DKA
⢠Hypersensitivity or sulfonamide allergy
contraindications for Sulfonylureas (SU)
Insulin
-first line therapy in T2DM if symptomatic or very high blood glucose levels
⢠Especially if catabolic features present (weight loss, hypertriglyceridemia, ketosis)
⢠To combination therapy if glycemic targets not met after 3 months of combo therapy
⢠Meglitinides
⢠Alpha-glucosidase inhibitors
⢠Bile acid resins/sequestrants
⢠Bromocriptine
⢠Pramlintide
Other FDA Approved Add-On Agents for T2DM Not Included in ADA Treatment Algorithm
Meglitinides/Glinides (GLNs)
-binds to site adjacent to the sulfonylurea receptor to stimulate insulin secretion from the β-cells of the pancreas in the presence of glucose
-an add on agent for T2DM
-consider with erratic meal intake
⢠Repaglinide
⢠Nateglinide
Meglitinides/Glinides (GLNs)
Meglitinides/Glinides (GLNs)
ADVERSE EFFECTS:
⢠Hypoglycemia (less than SUs)
⢠Weight gain
α-Glucosidase Inhibitors (AGi)
-competitively inhibits intestinal α-glucosidase enzymes that line the brush border of the small intestine (maltase, isomaltase, sucrase, glucoamylase)
⢠Delays the absorption and breakdown of sucrose and complex carbohydrates to monosaccharides
⢠Reduce rise in post prandial glucose
-Acarbose
-Miglitol
α-Glucosidase Inhibitors (AGi)
α-Glucosidase Inhibitors (AGi)
Contraindications:
⢠Chronic intestinal disease, inflammatory bowel disease, colonic ulceration or intestinal obstruction
α-Glucosidase Inhibitors (AGi)
⢠Must be taken 3x/day with first bite of each meal
⢠Decrease prandial insulin
dose if initiated together
⢠If hypoglycemia occurs,
glucose required
α-Glucosidase Inhibitors (AGi)
ADVERSE EFFECTS:
-undigested carbohydrates
leads to gas production due to their fermentation in the colon
⢠Flatulence, bloating, abdominal pain, diarrhea
Pramlintide
-Amylin analog
⢠Decrease glucagon secretion (decrease blood glucose)
⢠Promote satiety by delaying gastric emptying
-Adjunctive therapy added to prandial insulin
Pramlintide
ADVERSE EFFECTS:
-Hypoglycemia, nausea/vomiting, weight loss, headache
⢠Reduce prandial insulin dose by 30-50% when starting therapy
Pramlintide
Contraindications
⢠Confirmed gastroparesis
⢠Unable to detect hypoglycemia
Insulin
preferred agent for management in both T1DM and T2DM